JP2022536347A5 - - Google Patents

Info

Publication number
JP2022536347A5
JP2022536347A5 JP2021573426A JP2021573426A JP2022536347A5 JP 2022536347 A5 JP2022536347 A5 JP 2022536347A5 JP 2021573426 A JP2021573426 A JP 2021573426A JP 2021573426 A JP2021573426 A JP 2021573426A JP 2022536347 A5 JP2022536347 A5 JP 2022536347A5
Authority
JP
Japan
Prior art keywords
fusion protein
amino acid
substitutions
antibody
isolated fusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021573426A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022536347A (ja
JP7850417B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/037648 external-priority patent/WO2020252421A2/en
Publication of JP2022536347A publication Critical patent/JP2022536347A/ja
Publication of JP2022536347A5 publication Critical patent/JP2022536347A5/ja
Application granted granted Critical
Publication of JP7850417B2 publication Critical patent/JP7850417B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021573426A 2019-06-14 2020-06-13 新規インターロイキン-2バリアントおよびその二官能性融合分子 Active JP7850417B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962861484P 2019-06-14 2019-06-14
US62/861,484 2019-06-14
PCT/US2020/037648 WO2020252421A2 (en) 2019-06-14 2020-06-13 Novel interleukin-2 variants and bifunctional fusion molecules thereof

Publications (3)

Publication Number Publication Date
JP2022536347A JP2022536347A (ja) 2022-08-15
JP2022536347A5 true JP2022536347A5 (cg-RX-API-DMAC7.html) 2023-08-07
JP7850417B2 JP7850417B2 (ja) 2026-04-23

Family

ID=73782254

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021573426A Active JP7850417B2 (ja) 2019-06-14 2020-06-13 新規インターロイキン-2バリアントおよびその二官能性融合分子

Country Status (8)

Country Link
US (1) US20220170028A1 (cg-RX-API-DMAC7.html)
EP (1) EP3983001A4 (cg-RX-API-DMAC7.html)
JP (1) JP7850417B2 (cg-RX-API-DMAC7.html)
KR (1) KR102978756B1 (cg-RX-API-DMAC7.html)
CN (1) CN114728040A (cg-RX-API-DMAC7.html)
AU (1) AU2020292421B2 (cg-RX-API-DMAC7.html)
CA (1) CA3143038A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020252421A2 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3694870A1 (en) 2017-10-10 2020-08-19 Alpine Immune Sciences, Inc. Ctla-4 variant immunomodulatory proteins and uses thereof
CA3098930A1 (en) 2018-09-21 2020-03-26 Innovent Biologics (Suzhou) Co., Ltd. Novel interleukin-2 and use thereof
PE20221506A1 (es) * 2019-12-17 2022-10-04 Amgen Inc Agonista doble de interleucina-2/receptor de tnf para uso en terapia
KR20220140514A (ko) 2020-01-10 2022-10-18 브라이트 피크 테라퓨틱스 아게 변형된 il-2 폴리펩타이드 및 그의 용도
US12202882B2 (en) 2020-05-08 2025-01-21 Alpine Immune Sciences, Inc. APRIL and BAFF inhibitory immunomodulatory proteins and methods of use thereof
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
WO2022221746A1 (en) * 2021-04-16 2022-10-20 Orionis Biosciences, Inc. Il-2 based constructs
KR20240034221A (ko) 2021-07-09 2024-03-13 브라이트 피크 테라퓨틱스 아게 염증성 질환 및 자가면역 질환의 치료를 위한 변형된 il-2 폴리펩티드
JP7864826B2 (ja) * 2021-09-22 2026-05-25 フォートビタ バイオロジクス(シンガポール)プライベート リミティド インターロイキン2変異体およびその融合タンパク質
CN118414160A (zh) * 2021-10-06 2024-07-30 艾尔图制药公司 对发炎组织具有靶向特异性的白介素2嵌合构建体
US20250171531A1 (en) * 2022-02-10 2025-05-29 Orionis Biosciences, Inc. Il-2 trap molecules
WO2023180527A1 (en) 2022-03-25 2023-09-28 Universität Zürich Adenoviral mediated targeting of activated immune cells
IL317511A (en) 2022-06-16 2025-02-01 Cephalon Llc IL-2 immunoconjugates attenuated by anti-PD-1 antibody and their uses
US20260125451A1 (en) * 2022-08-29 2026-05-07 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Fusion protein comprising taci polypeptide and use thereof
EP4689123A1 (en) * 2023-03-29 2026-02-11 WuXi Biologics Ireland Limited Il-2 variants with improved stability and compositions thereof
EP4720125A1 (en) 2023-05-30 2026-04-08 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use
EP4762093A1 (en) 2023-08-14 2026-06-24 Paragon Therapeutics, Inc. Alpha 4 beta 7 integrin binding proteins and methods of use
EP4766723A1 (en) * 2023-08-23 2026-07-01 Depth Charge Ltd VARIANT PROTEINS OF INTERLEUKIN-2 THAT FACILITATE COVALENT CHEMICAL CONJUGATION AND THEIR USES
WO2025151752A1 (en) 2024-01-10 2025-07-17 Xilio Development, Inc. Masked il-2 cytokines and methods of use thereof
WO2026083295A1 (en) * 2024-10-16 2026-04-23 Bright Peak Therapeutics Ag Trispecific compositions comprising il-2, vegf binding domains, and pd-1 binding domains

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6955807B1 (en) * 1998-05-15 2005-10-18 Bayer Pharmaceuticals Corporation IL-2 selective agonists and antagonists
EP1454138B1 (en) * 2001-12-04 2012-01-18 Merck Patent GmbH Immunocytokines with modulated selectivity
KR20070003934A (ko) * 2004-03-05 2007-01-05 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 치료제의 환자 내약성을 예측하기 위한 시험관 내 테스트시스템
CN1930300A (zh) * 2004-03-05 2007-03-14 希龙公司 预测患者治疗药物耐受性的体外试验系统
CN102260352B (zh) * 2010-05-28 2013-11-20 山东先声麦得津生物制药有限公司 靶向性白细胞介素融合蛋白及其制备方法与应用
CN105440123B (zh) * 2011-02-10 2020-10-09 罗切格利卡特公司 突变体白介素-2多肽
PT3102595T (pt) * 2014-02-06 2019-01-11 Hoffmann La Roche Proteínas de fusão de interleucina-2 e suas utilizações
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
KR102379464B1 (ko) * 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
KR20190136076A (ko) * 2017-04-13 2019-12-09 에프. 호프만-라 로슈 아게 암 치료 방법에 사용하기 위한 인터루킨-2 면역접합체, cd40 작용제 및 임의적인 pd-1 축 결합 길항제
AU2018273914A1 (en) * 2017-05-24 2019-11-14 Pandion Operations, Inc. Targeted immunotolerance
US20200140547A1 (en) * 2017-05-26 2020-05-07 The Johns Hopkins University Multifunctional antibody-ligand traps to modulate immune tolerance
AU2019288496B2 (en) * 2018-06-22 2024-11-21 Cugene Inc. Interleukin-2 variants and methods of uses thereof
JP7778571B2 (ja) * 2019-06-05 2025-12-02 アッシャー バイオセラピューティクス, インコーポレイテッド 免疫細胞機能をモジュレートするための変異体インターロイキン-2ポリペプチドと抗原結合分子の融合体

Similar Documents

Publication Publication Date Title
JP2022536345A5 (cg-RX-API-DMAC7.html)
JP7317159B2 (ja) キメラ抗原受容体及びその使用方法
JP6783797B2 (ja) 抗がん融合ポリペプチド
AU2011240624B2 (en) TRAIL R2-specific multimeric scaffolds
JP2023182757A (ja) 調整可能な親和性を有する免疫調節タンパク質
US20210380701A1 (en) MULTIVALENT IgM- AND IgA-Fc-BASED BINDING MOLECULES
JP2020191862A5 (cg-RX-API-DMAC7.html)
JP2020198875A5 (cg-RX-API-DMAC7.html)
JP2020182458A5 (cg-RX-API-DMAC7.html)
JP2023506452A5 (cg-RX-API-DMAC7.html)
JP2022504868A (ja) 獣医学的使用のための、新生仔fc受容体(fcrn)への結合性が変化したfc変異体
JP2020511949A5 (cg-RX-API-DMAC7.html)
JP7356726B2 (ja) タンパク性ヘテロ二量体及びその使用
KR20160014010A (ko) 신규 항체
RS55609B1 (sr) Fc fuzioni proteini koji sadrže nove linkere ili aranžmane
CA2993891A1 (en) Interleukin-15 fusion proteins for tumor targeting therapy
WO2011076781A1 (en) Tetravalent cd47-antibody constant region fusion protein for use in therapy
WO2016124670A1 (en) Novel binding proteins comprising a ubiquitin mutein and antibodies or antibody fragments
RU2018104703A (ru) Опухолеспецифичное антитело против egfr и его применение
JP2018529327A5 (cg-RX-API-DMAC7.html)
JP2018536434A (ja) 腫瘍形質導入のための組成物及び方法
JP2020511144A5 (cg-RX-API-DMAC7.html)
CN111423512A (zh) 阻断血管内皮细胞生长且活化t细胞的多靶向融合蛋白和包含其的药物组合物
JP7303527B2 (ja) 新たな結合特異性を抗体に付与する超汎用法
JP2024535872A5 (cg-RX-API-DMAC7.html)